Neuromodulation of Cardiovascular Risks Associated With Cardiotoxic Chemotherapy

Recruiting now · Early Phase 1 · Has a placebo group

Conditions studied: Breast Cancer, Lymphoma

In brief

This study is to determine if low level vagus nerve stimulation will lead to improvement in heart function, heart rate variation, and in the levels of certain chemical markers of inflammation in study participants' blood.

Key facts

Study ID

NCT05921253

Run by

University of Oklahoma

People needed

104

Starts

2023-12-01

Expected to finish

2027-09-01

Last updated by the study team

2026-01-26

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients (>18 years) who have received anthracycline-based therapy for breast cancer or lymphoma within the last 30 days
• A least 1 of following additional criteria:
• previous chest radiation
• . Age>50
• type 2 diabetes mellitus
• hypertension
• current smoking
• obesity (BMI ≥ 30)
• previous myocardial infarction
• established atherosclerotic heart disease or significant valve disease. chronic kidney disease

You may not qualify if…

• Atrial paced rhythm
• History of seizure currently on treatment
• History of vasovagal syncope
• End stage liver or kidney disease

Where it is running

• Stephenson Cancer Center — Oklahoma City, Oklahoma, United States (enrolling)
• Stephenson Cancer Center- Tulsa — Tulsa, Oklahoma, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.